Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms
Centre National de la Recherche Scientifique · Institut Pasteur · +8 more institutions
Abstract
Efficient therapeutic options are needed to control the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that has caused more than 922,000 fatalities as of 13 September 2020. We report the isolation and characterization of two ultrapotent SARS-CoV-2 human neutralizing antibodies (S2E12 and S2M11) that protect hamsters against SARS-CoV-2 challenge. Cryo-electron microscopy structures show that S2E12 and S2M11 competitively block angiotensin-converting enzyme 2 (ACE2) attachment and that S2M11 also locks the spike in a closed conformation by recognition of a quaternary epitope spanning two adjacent receptor-binding domains. Antibody cocktails that include S2M11, S2E12, or the previously…
Citation impact
- FWCI
- 13.77
- Percentile
- 100%
- References
- 87
Authors
47- MAM. Alejandra TortoriciCorresponding
Centre National de la Recherche Scientifique, Institut Pasteur, University of Washington
- MBMartina BeltramelloCorresponding
Vir Biotechnology (Switzerland)
- FAFlorian A. Lempp
VIR Biotechnology (United States)
- DPDora Pinto
Vir Biotechnology (Switzerland)
- HVHa V. Dang
University of Washington
Topics & keywords
- Antibody
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
- Virology
- Epitope
- Severe acute respiratory syndrome
- Coronavirus
- Biology
- Effector
- Good health and well-being
Funding
- BWBurroughs Wellcome Fund
- BABill and Melinda Gates FoundationAwards: INV-006366, G0G4820N
- UOUniversity of Washington
- FGFast Grants
- NBNGM Biopharmaceuticals
- MModerna
- VBVir Biotechnology
- FWFonds Wetenschappelijk OnderzoekAward: G0G4820N
- KLKU LeuvenAward: G0G4820N
- PSPaul Scherrer Institut
- VRVlaamse regering
- UZUniversitaire Ziekenhuizen Leuven, KU LeuvenAward: G0G4820N
- NINational Institute of General Medical SciencesAwards: R01GM120553, GM120553
- NINational Institute of Allergy and Infectious DiseasesAwards: HHSN272201700059C, COVID-19